Protagonist Therapeutics, Inc.
NASDAQ:PTGXBiotechnology
+$1.72 today
- Market cap
- $8.30B
- Beta
- 1.83
- P/E (TTM)
- -64.2
- EPS (TTM)
- -$1.76
Volume 0.43M
Average 0.72M
PTGX Account Payables
Amounts the company owes suppliers for goods and services received.
Protagonist Therapeutics, Inc.NASDAQ: PTGX
Account Payables · Q2 FY2026 · quarter ended Jun 2026
Account payables rises 6.5% from a year ago
Account payables stood at $3.46M at the end of Q2 FY2026, up 6.5% from a year earlier and down 59.0% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Account payables amounted to 0.4% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +6.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 5.34M USD
- Year-over-year change
- +230.6%
- 4-year CAGR
- +35.2%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.34M | +230.6% |
| FY2024 | 2024-12-31 | 1.62M | +109.2% |
| FY2023 | 2023-12-31 | 772K | -78.8% |
| FY2022 | 2022-12-31 | 3.64M | +127.5% |
| FY2021 | 2021-12-31 | 1.6M | — |
Account Payables vs competitors
How PTGX compares with its peers on the latest reported figures
- PTGX's Jun 2026 account payables of $3.46M is the lowest of the 7 companies compared; the peer median is $8.49M.
- Its year-over-year change of +6.5% is the 5th highest of 7, against a peer median of +24.9%.
- Account payables amounts to 0.4% of total assets for PTGX, versus a peer median of 1.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $14.73M | +131.8% | +8.3% | 7.4% | |
| Mar 2026 | $10.51M | +90.9% | +33.3% | 5.5% | |
| Sep 2026 | $9.47M | +26.9% | +136.0% | 0.9% | |
| Mar 2026 | $7.52M | +22.8% | +11.6% | 2.3% | |
| Sep 2026 | $6.79M | -1.9% | +77.3% | 0.9% | |
IRONDisc Medicine, Inc. | Sep 2026 | $6.07M | -16.4% | -17.7% | 0.9% |
| Jun 2026 | $3.46M | +6.5% | +13.6% | 0.4% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding PTGX) | $8.49M | +24.9% | +22.5% | 1.6% | |
Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 123.67M | 125.74M | 186.73M | 97.25M | 128.39M |
| Short-term Investments | 203.24M | 111.61M | 154.89M | 321.66M | 438.97M |
| Net Receivables | 5.33M | 52K | 10.33M | 168.49M | 4.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 340.74M | 243.08M | 355.58M | 591.64M | 577.57M |
| Property, Plant & Equipment (Net) | 6.73M | 4.63M | 2.15M | 12.61M | 11.69M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 140.25M | 78.93M |
| Tax Assets | 0 | 0 | 0 | 0 | 1.71M |
| Other Non-current Assets | 225K | 225K | 225K | 225K | 0 |
| Total Non-current Assets | 6.96M | 4.85M | 2.37M | 153.08M | 92.32M |
| Total Assets | 347.7M | 247.93M | 357.95M | 744.73M | 669.89M |
| Account Payables | 1.6M | 3.64M | 772K | 1.62M | 5.34M |
| Short-term Debt | 0 | 0 | 0 | 510K | 2.28M |
| Tax Payables | 0 | 0 | 0 | 2.69M | 0 |
| Deferred Revenue | 2.5M | 69K | 0 | 18.89M | 9.55M |
| Other Current Liabilities | 7.13M | 4.97M | 6.79M | 12.62M | 15.51M |
| Total Current Liabilities | 44.02M | 31.18M | 21.27M | 47.4M | 45.44M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 221K | 0 | 1.71M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | (221K) | 11.68M | 0 |
| Total Non-current Liabilities | 3.66M | 1.14M | 0 | 22.03M | 9.74M |
| Total Liabilities | 47.67M | 32.32M | 21.27M | 69.43M | 55.19M |
| Common Stock | 0 | 0 | 1K | 1K | 1K |
| Retained Earnings | (409.36M) | (536.76M) | (615.71M) | (340.52M) | (470.67M) |
| Accumulated OCI | (299K) | (359K) | (105K) | (82K) | 641K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 300.02M | 215.61M | 336.68M | 675.3M | 614.71M |
| Total Debt | 5.86M | 3.66M | 1.14M | 10.87M | 10.32M |
| Net Debt | (117.81M) | (122.09M) | (185.59M) | (86.38M) | (118.07M) |
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
Intrinsic Alpha fair value
Locked
Current Price
$127.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.